Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Randomized, Sequential, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of a One-Time, Bilateral, Intraparenchymal Infusion of SPK-10001 Into the Caudate and Putamen in Participants With Huntington's Disease
Conditions
Interventions
SPK-10001
Placebo Surgery Control
Locations
5
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Cincinnati/Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Ohio State University
Columbus, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburg
Pittsburgh, Pennsylvania, United States
Start Date
February 21, 2025
Primary Completion Date
January 12, 2035
Completion Date
January 12, 2035
Last Updated
April 17, 2026
NCT07451613
NCT07253038
NCT04012411
NCT05326451
NCT03233646
NCT06774443
Reference Study ID Number: SPK-10001-101 https://forpatients.roche.com/
CONTACT
888-662-6728global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions